Legato Capital Management LLC Sells 17,347 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Legato Capital Management LLC decreased its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 28.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,285 shares of the biotechnology company’s stock after selling 17,347 shares during the quarter. Legato Capital Management LLC’s holdings in ADMA Biologics were worth $742,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Creative Planning boosted its position in ADMA Biologics by 73.9% during the second quarter. Creative Planning now owns 36,147 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 15,363 shares during the last quarter. CWM LLC raised its stake in shares of ADMA Biologics by 72.5% during the 3rd quarter. CWM LLC now owns 14,129 shares of the biotechnology company’s stock worth $282,000 after purchasing an additional 5,937 shares in the last quarter. Vontobel Holding Ltd. boosted its holdings in shares of ADMA Biologics by 7.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 888 shares during the last quarter. Inspire Advisors LLC bought a new position in shares of ADMA Biologics in the third quarter valued at $417,000. Finally, Veracity Capital LLC acquired a new position in ADMA Biologics during the third quarter worth $427,000. Institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

ADMA has been the subject of a number of recent analyst reports. HC Wainwright increased their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James lifted their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.70% of the company’s stock.

ADMA Biologics Trading Up 1.5 %

Shares of ADMA Biologics stock opened at $16.08 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The business has a fifty day simple moving average of $17.42 and a two-hundred day simple moving average of $17.75. ADMA Biologics, Inc. has a 1 year low of $5.02 and a 1 year high of $23.64. The company has a market capitalization of $3.80 billion, a price-to-earnings ratio of 57.43 and a beta of 0.75.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.